Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in so
- PDF / 237,867 Bytes
- 3 Pages / 595 x 842 pts (A4) Page_size
- 45 Downloads / 178 Views
memo (2020) 13:450–452 https://doi.org/10.1007/s12254-020-00662-5
Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors Gerald Prager · Armin Gerger · Gerald Höfler · Gerald Webersinke · Holger Rumpold · Thomas Winder · Rupert Bartsch · Matthias Preusser · Wolfgang Eisterer Received: 22 September 2020 / Accepted: 13 October 2020 / Published online: 11 November 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020
Summary The Austrian Society for Hematology and Medical Oncology (OeGHO) aimed to define a clear position on the importance of molecular diagnostics in solid tumors. This position covers the following four points: the indication for the assessment of a molecular profile has to be given by the treating medical oncologist depending on the course of the patient’s disease; the requirement that the molecular profile might lead to a therapeutic intervention in the individual patient; quality control of the molecular G. Prager · R. Bartsch · M. Preusser Clinical Department of Oncology, University Clinic for Internal Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria A. Gerger Clinical Department of Oncology, University Clinic for Internal Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria G. Höfler Diagnostic and Research Institute for Pathology, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria G. Webersinke Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz, Linz, Austria H. Rumpold Visceral Oncological Center, Ordensklinikum Linz, Linz, Austria T. Winder Internal Medicine II, Hematology, Oncology and Gastroenterology, Feldkirch University Teaching Hospital, Feldkirch, Austria W. Eisterer () Department of Internal Medicine and Hematology and Internal Oncology, Clinic of Klagenfurt a.W., Feschnigstraße 11, 9020 Klagenfurt, Austria [email protected]
450
analysis through proficiency testing and/or accreditation of the method used; and adherence to patient’s data safety according to data protection regulation. The present position paper does not cover the topic of germline mutations and other assessments in human genetics. Due to the fact that clinically relevant information on germline mutations may appear during the diagnostic processing we strongly recommend thorough patient education and documentation of patient consent. Keywords Molecular diagnostics · NGS · OeGHO · Position statement · solid tumors
Background The detection of molecular aberrations in solid tumors during recent years has led to a better understanding in tumor biology and enabled targeted therapy in the course of the disease. This scientific progress gave way to new therapeutic milestones in the treatment of solid tumors [1]. While the determination of certain molecular aberrations in different tumor types has become a standard approach for therapeutic decisions [2], a broader diagnostic intervention c
Data Loading...
